{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-23-000107","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.560918+00:00","generated_at":"2026-06-11T12:30:15.882842+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LianBio Q2 2023 net loss narrows to $21.6M; cash $267.3M; mavacamten NDA under priority review in China","bullets":["Net loss $21.6M in Q2 2023 vs $42.4M in Q2 2022; R&D expenses fell to $9.5M from $28.6M.","Cash, equivalents and marketable securities $267.3M at June 30, 2023; runway into first half 2025.","Mavacamten NDA accepted with priority review by China NMPA; approved in Singapore and Macau.","Phase 3 EXPLORER-CN met primary endpoint; data to be presented at ESC Congress 2023.","TP-03 Phase 3 LIBRA fully enrolled; infigratinib Phase 2a in gastric cancer showed 25% ORR."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-23-000107","json":"https://secwatch.observer/filing/0001831283-23-000107.json","markdown":"https://secwatch.observer/filing/0001831283-23-000107.md","text":"https://secwatch.observer/filing/0001831283-23-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000107/0001831283-23-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000107/lian-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:30:15.882842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c3d1285f8a2f323ed95a81c86c444b9182211ce","claim":"LianBio reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, LianBio (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000107/0001831283-23-000107-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}